SPRY

ARS Pharmaceuticals, Inc.
CAPPED RATING

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

ARS Pharmaceuticals, Inc. (SPRY) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B-); its weakest is Revisions (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
B-
Factor Score 3.0 / 5.0
Growth
B-
Factor Score 3.1 / 5.0
Profitability
C
Factor Score 2.4 / 5.0
Momentum
D
Factor Score 1.4 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -4.5
EV / EBITDA -2.3
Rev Growth YoY 16.0%
Gross Margin 45.9%
Price Return 3M -37.7%
Price Return 12M -56.5%
Catalyst Signal 0.00
Market Cap $391.1M
TTM Revenue $122.1M
Price / Sales 3.2
ROE -294.6%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B- (3.0) B- (3.1) C (2.4) D (1.4) F (0.0) C- (2.0)
2026-11-08 B- (3.0) B (3.2) C+ (2.6) D- (1.1) F (0.0) C- (2.0)
2026-11-01 B- (3.0) A- (3.9) C+ (2.8) D (1.3) C+ (2.7) C+ (2.7)
2026-10-25 B- (3.0) A- (3.9) C+ (2.8) D (1.3) C+ (2.6) C+ (2.7)
2026-10-18 B- (3.0) A- (3.9) C+ (2.8) D (1.2) C+ (2.6) C+ (2.7)
Page 1 of 3